Paterson, New Jersey Clinical Trials

A listing of Paterson, New Jersey clinical trials actively recruiting patient volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 44 clinical trials
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
Multi-center Open-label Phase 1b Study in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)

Primary Objectives: To evaluate the safety and tolerability of isatuximab administered subcutaneously (SC) versus intravenously (IV) To evaluate the pharmacokinetics (PK) of SC and IV isatuximab Secondary Objectives: To estimate absolute bioavailability of SC and IV isatuximab To measure receptor occupancy (RO) after isatuximab SC versus IV administration To assess …

hepatitis b surface antigen
hbv dna
dexamethasone
arginine hydrochloride
antibiotic therapy
Investigational Site Number 8400006
 (6.5 away) Contact site
  • 0 views
  • 24 Nov, 2025
  • +13 other locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B Secondary Objective: To characterize the safety and tolerability To characterize the pharmacokinetics (PK)

bethesda assay
antihemophilic factor
factor ix
hemophilia
fitusiran
Investigational Site Number 8400008
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +10 other locations
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated Nonsquamous NSCLC

This is a Phase 2, randomized, multicenter, double-blind study of the glutaminase inhibitor telaglenastat with standard-of-care pembrolizumab and chemotherapy versus placebo with standard-of-care pembrolizumab and chemotherapy for first line treatment of metastatic disease in patients with KEAP1/NRF2-mutated, stage IV, nonsquamous, non-small cell lung cancer (NSCLC). The study primary endpoints are …

carboplatin
metastasis
adjuvant therapy
stage iv non-small cell lung cancer
NTRK
New Jersey Cancer Care and Blood Disorders (NJCCBD)
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +27 other locations
A Safety Study of Oral Venetoclax in Combination With Intravenous Pembrolizumab in Adult Participants With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) With High Programmed Cell Death Ligand-1 (PD-L1) Expression

Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. It is the most common form of lung cancer, accounting for around 85% of lung cancers. The purpose of this study is to evaluate the safety and efficacy …

small cell lung cancer
growth factor
lymphoma
cancer
stage iv non-small cell lung cancer
Hackensack Univ Med Ctr /ID# 216484
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +38 other locations
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors

This research study is studying a new drug, NC410, as a possible treatment for advanced or metastatic solid tumors.

systemic therapy
oophorectomy
metastasis
measurable disease
bilateral oophorectomy
John Theurer Cancer Center at Hackensack University Medical Center
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • 1 location
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by …

high dose chemotherapy
lymphoma
high-dose chemotherapy
cancer
multiple myeloma
Hackensack Meridian Health
 (6.5 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +1 other locations
Double-Blind Multicenter Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19

This clinical trial will examine if a new treatment of Mesenchymal Stems Cells (called PLX-PAD) can help patients intubated and mechanically ventilated due to COVID-19 to recover more quickly with less complications.

respiratory distress
acute respiratory syndrome (sars)
acute respiratory distress
covid-19
SARS
Holy Medical Center
 (8.2 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +2 other locations
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

The ICGG Gaucher Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Gaucher disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The …

imiglucerase
deficiency
eliglustat
gaucher disease
Investigational Site Number 840057
 (1.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +220 other locations
Mucopolysaccharidosis I (MPS I) Registry

The Mucopolysaccharidosis I (MPS I) Registry is an ongoing, observational database that tracks the outcomes of patients with MPS I. The data collected by the MPS I Registry will provide information to better characterize the natural history and progression of MPS I as well as the clinical responses of patients …

Investigational Site Number 840057
 (1.4 away) Contact site
  • 0 views
  • 19 Feb, 2024
  • +135 other locations